Jarius, Sven
Paul, Friedemann
Weinshenker, Brian G.
Levy, Michael
Kim, Ho Jin
Wildemann, Brigitte
Article History
Accepted: 25 August 2020
First Online: 22 October 2020
Competing interests
: F.P. served on scientific advisory boards of MedImmune and Novartis; received travel funding and/or speaker honoraria from Alexion, Bayer, Biogen, Chugai, MedImmune, Merck Serono, Novartis, Sanofi-Aventis/Genzyme, Shire and Teva; is an associate editor of <i>Neurology, Neuroimmunology & Neuroinflammation</i>; is an academic editor of <i>PLoS ONE</i>; consulted for Alexion, Biogen, MedImmune, SanofiGenzyme and Shire; received research support from Alexion, Bayer, Biogen, Merck Serono, Novartis, Sanofi-Aventis/Geynzme and Teva; and has received research support from the Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program, German Ministry of Education and Research, German Research Council, Guthy–Jackson Charitable Foundation, National MS Society and Werth Stiftung of the City of Cologne. B.G.W. receives royalties from Hospices Civil de Lyon, Oxford University, RSR Ltd, and MVZ Labour PD Dr Volkmann und Kollegen GbR for a patent of NMO-IgG as a diagnostic test for NMO and related disorders (‘NMO-IgG: A Marker Autoantibody of Neuromyelitis Optica’); serves on an adjudication committee for clinical trials in NMO being conducted by Alexion and MedImmune, and consults for Chugai and Mitsubishi-Tanabe regarding a clinical trial for NMO. M.L. received consulting fees from Alexion, Genentech, and Viela Bio for participation in scientific advisory boards and receives consulting fees from Quest Diagnostics. H.J.K. received a grant from the National Research Foundation of Korea; consultancy/speaker fees from Alexion, Celltrion, Eisai, HanAll BioPharma, Merck Serono, Novartis, Sanofi Genzyme, Teva-Handok, and Viela Bio; is a steering committee member for MedImmune/Viela Bio; co-editor for <i>Multiple Sclerosis Journal</i> and associated editor for the <i>Journal of Clinical Neurology</i>. B.W. received research grants and/or honoraria from Bayer, Biogen, Deutsche Forschungsgemeinschaft (DFG), Dietmar Hopp Foundation, German Federal Ministry of Education and Research (BMBF; FKZ 01GI1602A), Klaus Tschira Foundation, Merck Serono, Novartis, Sanofi Genzyme and Teva. S.J. declares no competing interests.